IMPROVEMENT OF ACUTE AND CHRONIC RENAL DYSFUNCTION IN LIVER TRANSPLANT PATIENTS AFTER SUBSTITUTION OF CALCINEURIN INHIBITORS BY MYCOPHENOLATE MOFETIL
- 1 May 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 69 (9) , 1886-1890
- https://doi.org/10.1097/00007890-200005150-00025
Abstract
Background. Renal dysfunction caused by treatment with the calcineurin inhibitors (CNI) is a major problem in the long-term course after liver transplantation. Patients. In 22 liver graft recipients with renal dysfunction and stable graft function between 3 weeks and 12 years after transplantation, CNI were substituted by MMF at a final dose of 1.5–3 g/day between October 1996 and October 1998. Methods. In a prospective non-randomized study, the development of renal function, the side effects of MMF medication, and the stability of liver function were analyzed for a mean follow-up of 15 months. Results. (1) MMF was withdrawn in four patients for major side effects between 1 and 7 months after study entry; eight patients had minor side effects. (2) Six months after study entry, renal function had improved in 17 of the 22 study patients; mean serum creatinine ± SD (μmol/L) was 201±77 at entry and 153±65 after 3 months (P <0.001). (3) Improvement occurred in 11 of 15 patients with creatinine elevation ≥12 months and in 6 of 6 patients with creatinine elevation ≤6 months. (4) One patient developed transient liver dysfunction and a second required retransplantation for progressive cholestasis but without signs of rejection. Conclusions. In patients who undergo liver transplantation, substitution of CNI by MMF leads to improvement of acute as well as chronic renal dysfunction in most cases. Side effects of MMF may be limiting in some patients, and the immunological consequences remain to be studied.Keywords
This publication has 12 references indexed in Scilit:
- MYCOPHENOLATE MOFETIL MONOTHERAPY IN STABLE LIVER TRANSPLANT PATIENTS WITH CYCLOSPORINE-INDUCED RENAL IMPAIRMENTTransplantation, 1999
- COMPLETE CONVERSION OF IMMUNOSUPPRESSION FROM CYCLOSPORINE TO MYCOPHENOLATE MOFETIL IN PATIENTS WITH RENAL INSUFFICIENCY AFTER HTXTransplantation, 1999
- A PROSPECTIVE RANDOMIZED TRIAL OF TACROLIMUS AND PREDNISONE VERSUS TACROLIMUS, PREDNISONE, AND MYCOPHENOLATE MOFETIL IN PRIMARY ADULT LIVER TRANSPLANT RECIPIENTSTransplantation, 1998
- CHRONIC RENAL FAILURE FOLLOWING LIVER TRANSPLANTATIONTransplantation, 1998
- PROGRESSIVE HISTOLOGIC INJURY IN KIDNEYS FROM HEART AND LIVER TRANSPLANT RECIPIENTS RECEIVING CYCLOSPORINETransplantation, 1996
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- Mycophenolate mofetil: Molecular mechanisms of actionPerspectives in Drug Discovery and Design, 1994
- NEPHROTOXICITY FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATIONTransplantation, 1994
- Cyclosporine: mechanisms of action and toxicityCleveland Clinic Journal of Medicine, 1994
- Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejectionHepatology, 1994